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ABSTRACT 
Identification of neurodegeneration-monitoring biomarkers would be of great clinical 
value for Alzheimer´s disease (AD) diagnosis. Using N- or C-terminal antibodies, we 
studied the pro-survival synaptic effector, Kidins220, in the brain and cerebrospinal 
fluid (CSF) of controls and AD patients. Only the N-terminal antibody showed a 
positive correlation between Kidins220 and phosphorylated-tau in AD brains. Using 
this antibody, Kidins220 was detected in CSF from AD patients where it positively 
correlated with CSF phosphorylated-tau and tau. This study highlights the potential of 
Kidins220 to be used as a CSF biomarker in AD. 
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Alzheimer’s disease (AD), the most prevalent age-related dementia, is characterized 
by progressive neurodegeneration and severe synaptic and neuronal loss. 
Neuropathological hallmarks of AD are extracellular senile plaques containing 
amyloid-β (Aβ) and intracellular neurofibrillary tangles enriched in 
hyperphosphorylated-tau [1, 2]. Currently, reduced Aβ1-42 and increased 
phosphorylated-tau (p-tau) and tau levels in the cerebrospinal fluid (CSF) are used as 
diagnostic markers for AD	  [3, 4]. However, additional biomarkers for the early stages 
of AD pathogenesis could help improve AD diagnosis and monitor 
neurodegeneration. To this end, synaptic proteins in the CSF represent good 
candidates for further improving the prognostic accuracy of the AD biomarker panels 
[4]. 
Kinase D interacting substrate of 220 kDa (Kidins220) [5], also known as ankyrin 
repeat-rich membrane spanning “ARMS” [6], is an integral membrane protein present 
at the synapse where it is critical for neurotrophin and NMDARs signaling and 
neuronal survival [7, 8]. Dysfunctional neurotrophic support, synaptopathy and 
excitotoxicity (pathological overstimulation of the glutamate N-methyl-D-aspartate 
receptors; NMDARs) are involved in AD neurodegeneration [9], making Kidins220 a 
promising candidate. 
We have previously demonstrated an increase in Kidins220 in brains from AD 
patients concomitantly with Braak stage progression [10]. We also observed that, at 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Abbreviations: Kidins220, Kinase D-interacting substrate of 220 kDa; NMDARs, N-
Methyl-D-Aspartate type of glutamate receptors; CSF, cerebrospinal fluid; Aβ, 
Amyloid β; AD: Alzheimer's disease; NSE: Neuronal specific enolase; p-tau: 
phospho-tau 
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late Braak stages, Kidins220 accumulates within hyperphosphorylated tau 
aggregates of dystrophic neurites. Indeed, Kidins220 associates and shares common 
features with tau [10]. However, despite this initial observation, a thorough study of 
the correlation between Kidins220 and tau accumulation in the AD brain has yet to be 
reported.  
Here we have evaluated Kidins220 levels in AD and control brain samples, 
examining the potential correlation with tau. Due to the potential for Kidins220 as a 
biomarker for underlying neurodegeneration, we have also analyzed Kidins220 levels 
in CSF samples from our cohort of patients. 
MATERIALS AND METHODS 
 
Antibodies 
C-terminal and N-terminal Kidins220 rabbit polyclonal antibodies (Kidins220-Ct and 
Kidins220-Nt) and Kidins220 mouse monoclonal antibody (Kidins220-M) have been 
previously described [5, 11, 12]. Neuronal specific enolase (NSE) rabbit polyclonal 
antibody was from Millipore Corporation (Billerica, MA, USA). Aβ (6E10) and β-actin 
mouse monoclonal antibodies were from Covance (Salt Lake City, UT, USA) and 
Sigma-Aldrich (St Louis, MO, USA) respectively. PHF-1-p-tau antibody was a gift 
from Dr Davies (Albert Einstein College, NY, USA). Tau rabbit polyclonal antibody 
was purchased in DakoCytomation (Glostrup, Denmark). 
Human brain samples 
Brain tissue was collected by the Neurological Tissue Bank (Hospital Clínic, 
IDIBAPS, Barcelona, Spain) and the Neuropathology Institute Brain Bank (Hospital 
Universitari de Bellvitge, Hospitalet de Llobregat, Spain). Tissue collection and use 
was approved by the local Ethics Committee of the Tissue Bank and IIB-SantPau. 
Immunoblot analysis 
6	  	  
Protein brain homogenates and CSF samples (30 µl) were analysed by SDS-PAGE 
and immunoblot as previously described [10]. 
Clinical cohort 
Subjects from the Memory Unit (Hospital Santa Creu I Sant Pau) underwent formal 
cognitive evaluation [13] by neurologists with expertise in neurodegenerative 
diseases. Cognitively healthy control subjects showed results within the normal range 
and were negative for the core AD biomarkers based on our in-house criteria (CSF 
Aβ1-42 >550ng/ml, CSF t-tau <350ng/ml or CSF p-tau <61ng/ml) [14]. Patients with 
amnesic mild cognitive impairment (aMCI) were diagnosed according to NIA-AA 
criteria [15]. Patients with aMCI who were also positive for AD biomarkers (CSF Aβ1-
42 <550ng/ml, CSF t-tau >350ng/ml or CSF p-tau >61ng/ml) were classified as 
Prodromal AD due to the increased probability of conversion to AD [15]. Patients who 
met the criteria of the National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related Disorders Association [16] and 
were positive for AD biomarkers were classified as typical AD. All participants gave 
their written consent, and the study was approved by the local ethics committee 
following the ethical standards recommended by the Helsinki Declaration. 
CSF collection and assessment 
Collection of CSF was achieved by lumbar puncture according to international 
consensus recommendations [17]. Quantification of AD CSF biomarkers by ELISA 
was performed as previously described [14]. 
Quantification and Statistical analysis 
Full-length (FL) Kidins220 was quantified by densitometric analysis (NIH Image) after 
immunoblotting with Kidins220-Ct. Quantification values using Kidins220-Nt resulted 
from the sum of signals from FL and N-terminal fragments in brain or only FL in CSF. 
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Kidins220 levels were normalized to NSE in brain samples and to Ponceau staining 
in CSF samples, and expressed relative to the mean of controls. Signal for p-tau was 
normalized to tau and to NSE in brain samples. Student’s t-test was used to compare 
Kidins220 levels between controls and patients. Correlations between Kidins220, p-
tau, tau and Aβ1-42 were determined by Spearman’s Correlation test. Statistical 
analyses were performed using GraphPad Prism (San Diego, CA, USA). 
RESULTS 
Short post-mortem interval and detection of Kidins220 N-terminal region are 
critical factors to study Kidins220 in human brain. 
Initial studies on Kidins220 in AD were carried out on post-mortem brain samples 
using an antibody raised against the last 17 aminoacids of Kidins220 C-terminus 
(Kidins220-Ct) [10]. We have previously shown that Kidins220 very C-terminal end is 
lost after cleavage by the protease calpain in models of excitotoxicity and cerebral 
ischemia, and that cleaved-forms of the protein could only be detected by an 
antibody recognizing the N-terminal region (Kidins220-Nt) [7, 18]. Therefore, 
Kidins220-Ct signal could be severely diminished in situations where this protease is 
highly active, whilst the N-terminal signal may be preserved (see Figure 1A for details 
of antibodies and calpain-cleaved Kidins220 N-terminal fragments). 
Because calpain is activated in post-mortem tissue [19], we first evaluated the 
influence of post-mortem interval (PMI) on the ability of C-terminal and N-terminal 
antibodies to identify Kidins220 in human brain tissue. In order to strictly study the 
effect of increasing PMI, control and AD brain samples of short PMI (6 and 5h, 
respectively) were left at room temperature for additional periods of time before 
analysing Kidins220 by immunoblot (Figure 1B). Both antibodies detected a band 
corresponding to full-length (FL) Kidins220 but, as time increased, FL signal 
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disappeared and N-terminal fragments emerged, being still visible after 24h only with 
Kidins220-Nt (Figure 1B). Kidins220-Ct did not detect any proteolytic band (not 
shown).  
With this in mind, we examined Kidins220 levels using these two antibodies in brain 
necropsies over a range of PMI from AD patients and control individuals (see 
Supplementary Table 1 for clinical and demographic information). Quantification 
analysis of immunoblots showed that FL-Kidins220 detected by Kidins220-Ct 
negatively correlated with PMI both in control and AD samples (Figure 1C, left; 
r2(Cont, black line)=0.197, n=15, p<0.05; r2(AD, grey line)=0.311, n=20, p<0.05). 
However, Kidins220-Nt signal, considered as the sum of FL and N-terminal 
fragments, showed no significant correlation with PMI (Figure 1C, right; r2(Cont, black 
line)=0.009, n=15, p>0.05; r2(AD, grey line)=0.145, n=20, p>0.05). No differences in 
Kidins220 levels according to age or Braak stage were found using Kidins220-Nt (not 
shown). 
Kidins220 positively correlates with p-tau in human AD brain necropsies using 
a novel N-terminal antibody. 
Next, we compared Kidins220 levels between AD and control brain necropsies with a 
PMI of less than 8h to avoid potential loss of signal due to long PMI. Immunoblot and 
quantification analysis using both antibodies showed increased levels of Kidins220 in 
AD versus control samples (Figure 1D and 1E), being differences more evident with 
Kidins220-Nt (p<0.01) compared to Kidins220-Ct (p<0.05). Furthermore, Kidins220-
Nt revealed a positive correlation between Kidins220 and p-tau in AD samples 
(r2=0.236, n=17, p<0.05) (Figure 1F). Finally, immunofluorescence of human AD 
brain showed partial co-localization of Kidins220 with p-tau (Figure 1G). 
Kidins220 is present in CSF samples from AD patients and correlates with tau. 
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In order to evaluate Kidins220 as a CSF biomarker, CSF samples were obtained 
from 12 controls, 5 patients with aMCI, 4 prodromal AD and 9 AD patients (see 
supplementary Table 1 for demographic details). Immunoblot analysis with 
Kidins220-Nt showed Kidins220 presence, clearly more evident in some CSF 
samples from AD patients, while Kidins220-Ct rendered no specific bands (Figure 
2A). To confirm specificity of Kidins220 signal in CSF samples, we also tested a 
monoclonal antibody generated against 340 aminoacids of Kidins220 C-terminal 
region (Kidins220-M) [12]. This antibody detected FL-Kidins220 in those AD samples 
with higher Kidins220-Nt signal (Figure 2A). Although Kidins220-Nt labelled different 
bands in CSF it was difficult to undoubtedly identify the specific bands corresponding 
to the N-terminal fragments. Therefore, we only quantified Kidins220-FL-Nt band, and 
found it was significantly increased in CSF samples from AD patients (Figure 2B). In 
addition, in these patients there was a positive correlation between CSF Kidins220-Nt 
and p-tau (Figure 2C; r2(Cont, black line)=0.003, n=9; r2(AD, grey line)=0.744, n=9, 
p>0.01), and tau (Figure 2D; r2(Cont, black line)=0.001, n=9; r2(AD, grey line)=0.494, 
n=9, p>0.05) but no significant correlation with Aβ1-42 was found. 
DISCUSSION 
To evaluate Kidins220 as a potential biomarker for neurodegeneration, we have 
performed a quantitative study of Kidins220 in brain necropsies and CSF samples. 
Kidins220 was detected in human brain by immunoblot using two polyclonal 
antibodies that recognise either the carboxy- or amino-termini of Kidins220. We 
found a negative correlation between Kidins220 levels and PMI in human brain 
necropsies, which was specific to the use of the C-terminal antibody. Moreover, only 
the N-terminal Kidins220 signal correlated with p-tau levels in AD brains. Importantly, 
Kidins220-Nt antibody detected Kidins220 in CSF samples from AD patients where it 
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correlated positively with p-tau and tau content. Our results suggest that Kidins220 
could constitute a novel marker of AD neurodegeneration. 
In some CSF samples Kidins220 band was also visible using a monoclonal antibody 
raised against a big portion of Kidins220 C-terminal region but not with Kidins220-Ct 
that recognizes only last 17 aminoacids. These findings indicate that CSF may 
contain mainly N-terminal fragments of Kidins220 lacking the very C-terminal end 
after cleavage at the major identified calpain site (see scheme in Figure 1A), as has 
been reported in the ischemic brain [18]. The presence of transmembrane proteins in 
CSF is possible since cell-derived small vesicles known as exosomes have been 
detected in this biological fluid [20]. Indeed, transmembrane amyloid-related protein, 
as well as cytosolic proteins associated to exosomes such as tau, are found in CSF 
[21, 22]. In addition, excitotoxic calpain-derived Kidins220 N-terminal fragments could 
be formed intracellularly during neurodegeneration and released to the extracellular 
space, associated to exosomes or free, as a consequence of neuronal death.  
Our data demonstrate that Kidins220-Nt is a better tool for obtaining accurate and 
reproducible results in explorative studies of human post-mortem and CSF samples 
than Kidins220-Ct. The diagnostic and/or prognostic value of CSF Kidins220 needs 
to be explored in larger clinical longitudinal studies. More sensitive and specific 
methods to detect small amounts of this protein in CSF (such as ELISA) would be 
greatly beneficial for future studies.  
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FIGURE LEGENDS 
Figure 1. The use of an antibody recognizing Kidins220 N-terminal region is 
critical to study Kidins220 levels in post-mortem human brain samples and 
their correlation with phospho-tau in AD. A) Scheme of Kidins220 domains and 
regions recognized by the antibodies used. Estimated molecular weight of calpain-
derived N-terminal fragments is also shown. Kidins220-Ct recognizes last 17 
aminoacids. Kidins220-Nt was generated against the first 402 aminoacids. B) 
Immunoblot analysis of control and AD brain samples (6 and 5h PMI, respectively, 
considered time 0) left at room temperature for different times using Kidins220-Ct and 
Kidins220-Nt. Kidins220 full-length (FL) and N-terminal fragments are indicated. C) 
Correlation analysis of Kidins220 levels versus PMI obtained after immunoblot 
analysis of control and AD brain samples using Kidins220-Ct (left panel) and 
Kidins220-Nt (right panel) antibodies (Cont, black, n=15; AD, grey line and color 
scale for Braak stages, n= 20). Kidins220 values are given in arbitrary units 
expressed relative to the loading control NSE. D) Immunoblot analysis of a 
representative number of protein extracts from frontal cortex necropsies obtained 
from control subjects and AD patients. FL-Kidins220, Nt-fragments and proteins 
analyzed are indicated. E) Scatter dot plots analysis of the immunoblot bands after 
quantifying Kidins220 levels in control and AD brain samples using Kidins220-Ct (left 
panel) or Kidins220-Nt (right panel) antibodies. Kidins220 values are expressed in 
arbitrary units (a.u.) relative to the values of NSE and relative to the mean of the 
control group. Each symbol represents an individual (Cont, black, n=13; AD, grey line 
and color scale, n=17). Data show means±s.e.m. Unpaired t-test was performed 
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(*p<0.05, **p<0.01). F) Correlation analysis of Kidins220 versus p-tau levels from 
control and AD brain using Kidins220-Nt. Kidins220 and p-tau values are given in 
arbitrary units (a.u.) expressed relative to tau and NSE. Each symbol represents an 
individual (Cont, black, n=12; AD, grey line and color scale n=13). Correlation 
analyses were based on the Pearson’s analysis (*p<0.05). G) Immunofluorescence 
of Kidins220 (red) and p-tau (green) in human AD brain. Nuclei were stained with 
DAPI. Scale bar: 20 µm. 
Figure 2. Kidins220 is present in CSF from AD patients containing high levels 
of p-tau and tau. A) Immunoblot analysis of CSF samples from control subjects and 
patients diagnosed for aMCI, typical AD (AD) and atypical AD (AD*) (see 
supplementary Table 1 for details) using Kidins220-Ct, Kidins220-Nt and Kidins220-
M antibodies. FL-Kidins220 is indicated. Extracts from cultured rat cortical neurons 
(Neu) are included as positive control for Kidins220 signal. B) Scatter dot plots 
analysis of Kidins220-FL-Nt signal in CSF samples. Kidins220 values are expressed 
in arbitrary units (a.u.) relative to the values of total protein after Ponceau staining 
and relative to the mean of the control group. Each symbol represents an individual 
(Cont, n=10; aMCI, n=5; pro AD, n=4; AD+AD*, n=9). Data show means±s.e.m. 
Unpaired t-test was performed (*p<0.001). C-D) Correlation analysis of Kidins220 
versus p-tau and tau levels from control and AD patients using Kidins220-Nt. 
Kidins220 values are given in arbitrary units (a.u.) and p-tau and tau levels in pg/ml. 
Each symbol represents an individual (Cont, black, n=10; AD+AD*, grey line and 





Supplementary Table 1: Left side: Age (years), gender and post-mortem interval in hours (PMI (h)) of control (C) and AD patients. Braak stage progression is also indicated (I-VI). Right side: Diagnosis and CSF levels of p-tau, tau and Aβ1-42 (pg/ml) in controls (C) and patients (P). 
Brain Age Gender PMI (h) Braak  CSF Diagnosis p-tau tau Aβ1-42 
C-1 74 F 3,7   C-1 
Cognitively healhy controls (AD biomarker negative) 
38 196 734 C-2 78 M 2,25   C-2 38 211,5 906 C-3 64 M 3,5   C-3 37,5 230,5 901 C-4 56 M 3,8   C-4 49,5 311 940,5 C-5 85 M 5,75   C-5 52 302,5 891,5 C-6 81 F 4   C-6 36,5 159 590 C-7 39 M 3,5   C-7 29,5 208 917 C-8 78 F 3,7   C-8 40 200,5 742,5 C-9 67 M 5   C-9 55,35 256,1 877,85 C-10 24 F 6   C-10 54 321,5 1177,5 C-11 66 M 7   C-11  54 294 698,5 C-12 59 M 6,4   C-12  54,5 265,5 806 C-13 64 F 5   P-1 
Amnesic MCI  
41 173 841 C-14 59 M 16,5   P-2 46,5 300 1115,5 C-15 57 M 20,5   P-3 48 193 659,5 AD-1 64 F 2,3 I  P-4 44 208 607,5 AD-2 54 M 3,2 I  P-5 53 292,5 472,5 AD-3 57 F 5 I  P-6 Prodromal AD (Amnesic MCI + AD biomarker positive) 
85,5 492,5 463,5 AD-4 65 F 3,4 III  P-7 95 741 518 AD-5 80 F 2,45 IV  P-8 73 497 450,5 AD-6 79 M 2,45 IV  P-9 156,5 873,5 462,5 AD-7 74 M 4,45 IV  P-10 
Typical AD (AD biomarker positive) 
103 756 435,5 AD-8 87 M 8 V  P-11 98 767,5 490,5 AD-9 64 M 14,8 V  P-12 82 880,5 369,5 AD-10 75 M 2,5 VI  P-13 99,5 942 168,5 AD-11 69 M 3,5 VI  P-14 112,5 1295 322 AD-12 75 M 4,25 VI  P-15 124,5 1661,5 403 AD-13 83 F 4,5 VI  P-16 95 1680,5 379,5 AD-14 61 F 4,5 VI  P-17 206 1784 527 AD-15 83 M 5 VI 
 P-18 
AD* (Atypical AD; AD biomarker positive + suspected semantic dementia) 
130,5 870,5 199,5 
AD-16 53 M 5,25 VI AD-17 44 M 5,5 VI AD-18 60 M 7,25 VI AD-19 48 M 9,5 VI AD-20 48 M 15,3 VI Brain:  PMI Mean: C=6,4h; AD=5,6h              CSF:     p-tau Mean: C=45; aMCI=47; Pro AD=103 ; AD=115 (pg/ml) Age Mean: C=63,4y; AD=66,2y          tau Mean: C=246; aMCI=233; Pro AD=651 ; AD=1221 (pg/ml)               Aβ1-42 Mean: C=849; aMCI=739; Pro AD=474 ; AD=387 (pg/ml)    
